Orphai Therapeutics is advancing LAM-001 for Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD), Bronchiolitis Obliterans Syndrome post lung transplant (BOS) and Sarcoidosis Associated Pulmonary Hypertension (SAPH).
